JP2006514116A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514116A5
JP2006514116A5 JP2005510345A JP2005510345A JP2006514116A5 JP 2006514116 A5 JP2006514116 A5 JP 2006514116A5 JP 2005510345 A JP2005510345 A JP 2005510345A JP 2005510345 A JP2005510345 A JP 2005510345A JP 2006514116 A5 JP2006514116 A5 JP 2006514116A5
Authority
JP
Japan
Prior art keywords
medicament
prevention
patient
item
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005510345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514116A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038175 external-priority patent/WO2004047771A2/en
Publication of JP2006514116A publication Critical patent/JP2006514116A/ja
Publication of JP2006514116A5 publication Critical patent/JP2006514116A5/ja
Pending legal-status Critical Current

Links

JP2005510345A 2002-11-25 2003-11-25 血管形生、細胞移動、細胞侵入及び細胞増殖を阻害するペプチド、組成物及びそれらの使用 Pending JP2006514116A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42917402P 2002-11-25 2002-11-25
US47553903P 2003-06-02 2003-06-02
PCT/US2003/038175 WO2004047771A2 (en) 2002-11-25 2003-11-25 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2006514116A JP2006514116A (ja) 2006-04-27
JP2006514116A5 true JP2006514116A5 (enExample) 2007-02-15

Family

ID=32397181

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005510345A Pending JP2006514116A (ja) 2002-11-25 2003-11-25 血管形生、細胞移動、細胞侵入及び細胞増殖を阻害するペプチド、組成物及びそれらの使用
JP2005512876A Pending JP2006515866A (ja) 2002-11-25 2003-11-25 腫瘍および内皮細胞を標的とするペプチド、その組成物および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005512876A Pending JP2006515866A (ja) 2002-11-25 2003-11-25 腫瘍および内皮細胞を標的とするペプチド、その組成物および使用

Country Status (14)

Country Link
US (2) US20050020810A1 (enExample)
EP (2) EP1569678A4 (enExample)
JP (2) JP2006514116A (enExample)
KR (2) KR20050096917A (enExample)
AU (2) AU2003297609A1 (enExample)
BR (2) BR0316523A (enExample)
CA (2) CA2506813A1 (enExample)
EA (2) EA200500871A1 (enExample)
HR (2) HRP20050585A2 (enExample)
MX (2) MXPA05005469A (enExample)
NO (2) NO20053112L (enExample)
NZ (2) NZ540363A (enExample)
PL (2) PL377763A1 (enExample)
WO (2) WO2004063213A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL377763A1 (pl) * 2002-11-25 2006-02-20 Attenuon, Llc. Peptydy, które hamują angiogenezę, migrację komórek, naciekanie komórkowe i proliferację komórkową oraz kompozycje zawierające te peptydy i ich zastosowania
CA2566897A1 (en) * 2004-05-21 2005-12-01 Mds Inc. Doing Business Through Its Mds Pharma Services Division Method of quantifying the cell-binding properties of a medical device
US20060078535A1 (en) * 2004-10-13 2006-04-13 The Regents Of The University Of Michigan Anticancer compounds and methods
EP1843779A2 (en) * 2005-02-01 2007-10-17 Attenuon, LLC Compositions containing the anti-angiogenic phscn-peptide
US20080261892A1 (en) 2005-02-01 2008-10-23 Ternansky Robert J Acid Addition Salts of Ac-Phscn-Nh2
AU2016213759B2 (en) * 2006-11-08 2018-03-29 Chongxi Yu Transdermal delivery systems of peptides and related compounds
AU2006350707A1 (en) * 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
PL2427475T3 (pl) 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
KR101228668B1 (ko) 2010-09-17 2013-01-31 가톨릭대학교 산학협력단 혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도
WO2012178023A1 (en) 2011-06-23 2012-12-27 Board Of Regents, The University Of Texas System Identifying peptides at the single molecule level
US11435358B2 (en) 2011-06-23 2022-09-06 Board Of Regents, The University Of Texas System Single molecule peptide sequencing
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
JP6206987B2 (ja) * 2012-05-11 2017-10-04 メディカス バイオサイエンシーズ，エルエルシー 網膜剥離の処置のための生体適合性ヒドロゲル製剤
CA2875369C (en) 2012-06-04 2017-11-21 Suncor Energy Inc. Formulations containing paraffinic oil and anti-settling agent
CA2877585C (en) 2013-03-15 2016-04-12 Suncor Energy Inc. Herbicidal compositions
JP5970439B2 (ja) * 2013-09-20 2016-08-17 チョンシー ユー ペプチド及び関連化合物の経皮送達システム
CA2961493C (en) * 2014-09-15 2023-10-03 Board Of Regents, The University Of Texas System Improved single molecule peptide sequencing
CN112513269A (zh) 2018-07-12 2021-03-16 德克萨斯大学系统董事会 通过寡核苷酸进行分子邻域检测
EP3861009A4 (en) 2018-10-05 2023-01-11 Board of Regents, The University of Texas System DETECTION AND RELEASE OF N-TERMINAL SOLID PHASE PEPTIDE
EP3923729B1 (en) 2019-02-15 2025-08-13 Nutrien Ag Solutions (Canada) Inc. The use of protoporphyrin ix derivatives to improve the health of plants

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
WO1981003330A1 (fr) 1980-05-13 1981-11-26 Mitsubishi Chem Ind Derives de la cysteine et leur production
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
US4394519A (en) * 1982-01-19 1983-07-19 Research Corporation Amino acid blocking agents
GB8504253D0 (en) * 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5608110A (en) * 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
IL117474A (en) * 1995-03-14 2001-04-30 Siemens Ag Removable precise dosing unit containing inhaled drugs for a hearing aid device
ZA962077B (en) * 1995-03-14 1997-03-26 Siemens Ag Ultrasonic atomizer device with removable precision dosating unit
US5618513A (en) * 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
CA2265484C (en) * 1996-09-10 2008-12-02 The Burnham Institute Tumor homing molecules, conjugates derived therefrom, and methods of using same
US6001965A (en) * 1996-11-21 1999-12-14 The Regents Of The University Of Michigan Anticancer compounds and methods
US6025150A (en) * 1996-11-21 2000-02-15 The Regents Of The University Of Michigan Methods and compositions for wound healing
US6331409B1 (en) * 1996-11-21 2001-12-18 The Regents Of The University Of Michigan Methods and compositions for wound healing
WO1998030538A1 (en) * 1997-01-14 1998-07-16 Kaneka Corporation Process for producing cysteine derivatives
US5994309A (en) * 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
AU9477398A (en) * 1997-09-10 1999-03-29 Burnham Institute, The Methods of identifying molecules that home to angiogenic vasculature in tumors
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
AU5671099A (en) * 1998-08-14 2000-03-06 The Administrators Of The Tulane Eductional Fund Compounds having growth hormone releasing activity
ATE366936T1 (de) 2001-01-18 2007-08-15 Univ Michigan Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
PL377763A1 (pl) 2002-11-25 2006-02-20 Attenuon, Llc. Peptydy, które hamują angiogenezę, migrację komórek, naciekanie komórkowe i proliferację komórkową oraz kompozycje zawierające te peptydy i ich zastosowania

Similar Documents

Publication Publication Date Title
JP2006514116A5 (enExample)
JP2003503454A5 (enExample)
IL190150A0 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
HUS1500021I1 (hu) 1,2,4-oxadiazol-benzoesav vegyületek és alkalmazásuk nonszensz szupresszióra és a betegség kezelésére
JP2007523178A5 (enExample)
IL189500A (en) 4, 2-Diaminopyrimidines are preserved in position 5, containing pharmaceutical preparations and using them to prepare a drug for the treatment of 3x2p receptor mediated diseases and 2/3 x2p
JP2005507892A5 (enExample)
JP2003526626A5 (enExample)
ZA200203156B (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders.
GB2368525B (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
JP2005511619A5 (enExample)
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
JP2008513426A5 (enExample)
JP2009516719A5 (enExample)
SI1545710T1 (sl) Uporaba N-(3-metoksi-5-metilpirazin-2-il)-2-(4-(1,3,4-oksadiazol-2-il)fenil) piridin-3-sulfonamida v zdravljenju raka
JP2005507888A5 (enExample)
TW200509909A (en) Use of organic compounds
JP2008513427A5 (enExample)
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
JP2005505605A5 (enExample)
JP2005523891A5 (enExample)
JP2004521140A5 (enExample)
WO2003097163A3 (en) Using a selective inos inhibitor for the treatment of respiratory diseases and conditions
JP2006500398A5 (enExample)
JP2006505577A5 (enExample)